STOCKHOLM--(BUSINESS WIRE)--At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5' ...
EnginZyme reports that it has patented a process to synthesize pseudouridine, a key ingredient in mRNA COVID-19 vaccines. The company and its CDMO partner, Ajinomoto Bio-Pharma Services, say they ...
When it comes to mRNA injections for COVID, Americans are 100% dependent on the FDA and vaccine manufacturers to assess and confirm purity and consistency. That might be okay if the testing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results